Acadia Pharma (ACAD) Misses Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $21.03 +2.24%
Revenue Growth %: +19.3%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
ATS, SICP, FTCO, More
Revenue Growth %: +19.3%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q1 EPS of ($0.45), $0.03 worse than the analyst estimate of ($0.42).
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CPS Technologies (CPSH) Reports In-Line Q3 EPS
- SmartRent (SMRT) Reports In-Line Q3 EPS
- Studio City International Holdings Limited (MSC) Reports Q3 Loss of $0.02
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
